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Abstract 
Background: Children with moderate acute malnutrition (MAM) are treated with lipid-based 1 
nutrient supplements (LNS) or corn-soy-blends (CSB) but little is known about their impact 2 
on hemoglobin (Hb), iron status and inflammation. 3 
Objective: The objective was to investigate the impact of supplementary foods for treatment 4 
of MAM on Hb, iron status, inflammation and malaria.   5 
Design: A randomized 2x2x3 factorial trial was conducted in Burkina Faso. Children aged 6-6 
23 months with MAM received 500 kcal/day as LNS or CSB, containing either dehulled soy 7 
(DS) or soy isolate (SI) and different quantities of dry skimmed milk (0, 20 or 50% of total 8 
protein) for 12 weeks. The trial was double-blind with regard to quality of soy and quantity of 9 
milk, but not matrix (CSB vs LNS). Hb, serum ferritin (SF), serum soluble transferrin 10 
receptor (sTfR), serum C-reactive protein (CRP), serum α1-acid glycoprotein (AGP) and 11 
malaria antigens were measured at inclusion and after supplementation (ISRCTN42569496). 12 
Results: Between September 2013 and August 2014, 1609 children were enrolled. Among 13 
these, 61 (3.8%) were lost to follow-up. During the 12-week supplementation period, 14 
prevalence of anemia, low SF adjusted for inflammation (SFAI), elevated sTfR and iron 15 
deficiency anemia decreased by 16.9, 8.7, 12.6 and 10.5 percentage points. Children who 16 
received LNS compared to CSB had higher Hb (2 g/L, 95% CI: 1, 4), SFAI (4.2 µg/L, 95% 17 
CI: 2.9, 5.5), and CRP (0.8 mg/L, 95% CI: 0.4, 1.2) and lower sTfR (-0.9 mg/L, 95% CI: -18 
1.3, -0.6) after the intervention. Replacing dehulled soy with soy isolate or increasing milk 19 
content, did not affect Hb, SFAI, sTfR or CRP.  20 
Conclusion: Supplementation with LNS compared to CSB led to better Hb and iron status, 21 
but overall prevalence of anemia remained high. The higher concentrations of acute phase 22 
proteins in children who received LNS requires further investigation. 23 
 24 
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Introduction 27 
 28 
Moderate acute malnutrition (MAM) is defined by a weight-for-height z-score (WHZ) <-2 29 
and ≥-3 (moderate wasting) and/or a mid-upper arm circumference <125 mm and ≥115mm 30 
(1). While the number of children with MAM based on the above definition is unknown, it 31 
has been estimated that 33 million children suffer from moderate wasting alone (2). MAM 32 
occurs in both non-emergency and emergency settings. In non-emergency settings it may be 33 
possible to improve nutritional status through nutrition counselling and optimizing intake of 34 
family foods. In emergency settings however, where energy and nutrient needs cannot be met 35 
using local foods, MAM is treated with supplementary foods either in the form of fortified 36 
blended foods, such as corn-soy blends, or lipid-based nutrient supplements (LNS) (3). To 37 
date there are still questions regarding the effectiveness of MAM programs in emergencies 38 
(3). In 2012, WHO published a proposed nutrient composition for supplementary foods for 39 
children with MAM but called for more research (4).  40 
 41 
Studies investigating different food supplements for MAM treatment have mainly assessed 42 
anthropometric outcomes (5–11). However, anthropometric deficits are likely to be 43 
accompanied by micronutrient deficiencies and the return to anthropometric measurements in 44 
the normal range does not necessarily mean that children are well-nourished in terms of 45 
micronutrient status. Anemia affects an estimated 71% of under 5 year old children in west 46 
and central Africa (12). Anemia leads to shortness of breath, fatigue and has been associated 47 
with poor cognitive development, impaired work capacity and increased susceptibility to 48 
infections (13). Two of its predominant causes, namely iron deficiency and infection, 49 
especially malaria, are common in children with MAM in Burkina Faso (14,15). 50 
 51 
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We have previously described the impact of food supplements either in the form of LNS or 52 
corn-soy blends (CSB), with either soy isolate (SI) or dehulled soy (DS) and with different 53 
quantities of dry skimmed milk (DSM) on anthropometric outcomes and accretion of fat-free 54 
tissue  in children with MAM (16). The objective of this paper was to investigate the impact 55 
of these supplements on hemoglobin, iron status, inflammation and malaria.   56 
 57 
Subjects and methods 58 
Study area and participants 59 
This study was part of the Treatfood trial, a randomized trial with a 2x2x3 factorial design, 60 
investigating the effectiveness of food supplements for the treatment of MAM. As previously 61 
described (16), research sites were constructed at 5 governmental health centers 62 
(Gomponsom, Latoden, Bagaré, Bokin and Samba) in the Province du Passoré, Northern 63 
Region, Burkina Faso and staffed by the Alliance for International Medical Action. The 64 
catchment area covered 143 villages with a total population of ~258,000.  65 
 66 
Screening for participants took place in villages either by community health workers using 67 
mid-upper arm circumference (MUAC) tapes or by designated screening teams using both 68 
MUAC and WHZ. Children could also present at the site based on the caregiver’s initiative or 69 
be referred from a health center. A final assessment for eligibility was carried out by study 70 
staff at the sites. Children with MAM were enrolled in the trial if they were aged 6-23 71 
months, resident in the catchment area and their parents/caregivers had given informed 72 
consent for the children to participate. Children who were enrolled in another nutritional 73 
program, had been treated for severe acute malnutrition (SAM) or been hospitalized in the 74 
last two months, had an illness requiring hospitalization, a hemoglobin <50 g/L, a suspected 75 
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allergy to milk, peanuts, CSB or LNS, or a severe disability were not eligible. Recruitment 76 
took place from September 2013 until August 2014.  77 
 78 
Randomization and supplementary foods 79 
Stratified, block randomization was used to allocate participants to one out of 12 80 
supplements, where stratification was done by site and block sizes were either 12 or 24.  81 
Blocked randomization was used to ensure that children were allocated evenly to the trial 82 
arms and different block sizes were used to make the allocation process less predictable. 83 
Random sequences were created by a person otherwise not involved in the trial using 84 
www.randomization.com. 85 
 86 
Supplements were either a LNS or a CSB (referred to as the matrix) with either DS or SI and 87 
either 0%, 20% or 50% of protein from DSM (M0, M20 or M50) (Table 1). The trial was 88 
double-blind with respect to soy quality and milk content, but not matrix. Supplements were 89 
designated by a 1-letter code by the manufacturer, and a code-key was kept in a sealed 90 
envelope in a safe. The supplements were packed in individual boxes containing a full 12-91 
week treatment for 1 participant (either 6 bags of CSB or 84 sachets of LNS). During 92 
production, each box, bag and sachet was labelled with a 12-letter sequence containing the 93 
relevant 1-letter code in a fixed position and the 11 remaining letters in random order. Only 94 
one individual in Burkina Faso, otherwise not involved in recruitment and data collection was 95 
aware of the position of the 1-letter code. This individual relabelled boxes and supplements 96 
with individual study identification numbers (IDs). At enrolment, children were given a study 97 
ID by staff without access to the random sequences or supplements. 98 
 99 
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Each participant received the allocated supplement for a 12-week period, even if they 100 
recovered from MAM before. LNS products were provided in individual sachets of 92 g per 101 
daily ration and CSB products were provided in 1.7 kg bags per 14-day ration. All 102 
supplements consisted of 500 kcal per daily serving (120 g of CSB or 92 g of LNS). LNS 103 
products were ready-to-use and CSB products needed to be cooked using water and 104 
consumed as a porridge. Supplements were manufactured by GC Rieber Compact A/S 105 
(Bergen, Norway), who were otherwise not involved in the trial design or interpretation of 106 
data. Nutrient composition of products complied with WHO’s technical note for the 107 
management of MAM (4). The recipes (16) and micronutrient composition (17) of these 108 
products have previously been published. Briefly, the supplements contained approximately 109 
12 mg of elemental iron added in the form of ferrous gluconate, 14 mg of zinc (as zinc 110 
gluconate) and 1.15 mg of copper in the form of copper gluconate. Content of water soluble 111 
vitamins was higher in CSBs to account for degradation during cooking. Vitamin C content 112 
for example was doubled in CSB compared to LNS (188 mg vs 94 mg) and vitamin B12 was 113 
4.1 µg in CSB products and 3.2 µg in LNS. 114 
 115 
Data collection 116 
During the intervention period children visited the health center every 2 weeks.  Children 117 
who missed scheduled visits were visited by community health workers and encouraged to 118 
return for follow-up. At baseline, study nurses collected information about sociodemographic 119 
characteristics, 2-week retrospective morbidity as well as vaccination status and carried out a 120 
clinical examination. Children who were not up-to-date with vaccinations were referred to a 121 
health center. Children received albendazole (200 mg if < 8 kg; 400 mg > 8 kg) and vitamin 122 
A (100,000 IU if 4-8 kg; 200,000 IU if >8 kg) if they had not received a supplement in the 123 
previous 6 months. Weight was measured to the nearest 100 g using an electronic scale with 124 
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double weighing function (Seca model 881 1021659). Length was measured to the nearest 1 125 
mm with a wooden height board once a month. WHZ was determined at sites using WHO 126 
field tables and later recalculated using the package “zscore06” in STATA 12 (College 127 
Station, Texas, USA). MUAC was measured on the left arm to the nearest 1 mm using a 128 
standard measuring tape. Anthropometric measurements were taken in duplicate by trained 129 
staff. A qualitative 24-hour recall was used to collect dietary data. Venous blood was 130 
collected from the arm at baseline and after the supplementation period.  One drop was used 131 
for diagnosis of malaria (Plasmodium falciparum) using a rapid diagnostic test (SD Bioline 132 
Malaria Ag Pf) and one drop was used to measure hemoglobin (Hb) on site using a HemoCue 133 
device (Hb 301, Ängelholm, Sweden). The HemoCue was calibrated at the end of every 134 
month with a control solution. The remaining blood was put into a sample tube with clot 135 
activator (BD reference #368492) and transported to the trial laboratory in a cold box at 2-136 
8°C. Serum was isolated following centrifugation (EBA 20 S Hettich) and stored at -20°C 137 
until shipment to VitMin Lab in Willstaedt, Germany for analysis. Serum C-reactive protein 138 
(CRP), α1-acid glycoprotein (AGP), serum soluble transferrin receptor (sTfR) and serum 139 
ferritin (SF) were determined using a combined sandwich enzyme-linked immunosorbent 140 
assay (18). All samples were measured in duplicate and the intra- and interassay coefficients 141 
of variation were <10%. Samples were frozen and thawed only once prior to analysis. 142 
The thresholds used for defining abnormal values were as follows: Hb <110 g/L (19), SF <12 143 
µg/L (19), sTfR >8.3 mg/L (18), CRP >10mg/l (20), AGP >1 g/L (21). Since SF is affected 144 
by inflammation and therefore does not reliably reflect iron status in populations where 145 
inflammation is common, SF was adjusted for inflammation prior to analysis using regression 146 
models as previously described (15) and is referred to as SF adjusted for inflammation 147 
(SFAI). Iron deficiency anemia (IDA) was defined as Hb < 110g/L and SFAI < 12 µg/L. 148 
 149 
11 
 
Statistical analyses 150 
To be able to detect a 0.6 SD difference between any 2 combinations of the 3 factors with 151 
80% power and a 5% significance level, while allowing for 20% loss to follow-up the 152 
required sample size was 134 children per arm or 1608 in total (16). A 0.6 SD difference 153 
approximately translates to a 10g/L difference for Hb, a 1.6µg/L difference for SFAI, a 154 
0.9mg/L difference for sTfR, a 3.4 mg/L difference for CRP and a 0.95 g/L difference for 155 
AGP.  The outcomes reported here, namely Hb, sTfR, SF, CRP and AGP were secondary 156 
outcomes of the trial. The primary outcome which was an increment in fat-free tissue has 157 
been reported elsewhere (16). 158 
 159 
Data were double entered into Epidata 3.1. software (Epidata Association, Odense, Denmark) 160 
and double entry checks were carried out on a daily basis. All statistical analyses were carried 161 
out using STATA 12. Characteristics of the study population were summarized as percentage, 162 
mean ± SD or, if not normally distributed, as median (interquartile range). Chi2 tests were 163 
used to test for differences in proportions. T-tests and one-way ANOVAs were used to test 164 
for differences in means for 2 or more groups, respectively. Changes in concentrations of Hb, 165 
and of biomarkers of iron status and inflammation before and after the intervention were 166 
assessed using t-tests. McNemar’s Chi2 was used to test for differences in proportions over 167 
time.  168 
 169 
The main analysis was based on the intention-to-treat (ITT) principle using available-case 170 
data. A per protocol (PP) analysis was also carried out. Linear mixed models were used to 171 
evaluate the effect of matrix, soy quality and amount of DSM on Hb, SF, SFAI, sTfR, CRP 172 
and AGP and logistic mixed models for the effect on malaria. Site was included in the model 173 
as a random effect. As a first step, all 3-way interactions between the 3 factors (matrix, 174 
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quality of soy and quantity of milk) were tested for using likelihood ratio tests and, where 175 
possible, reduced to 2-way interactions or main effects. Pairwise comparisons of means were 176 
then performed using model-based post-hoc tests in the reduced models. Where it was not 177 
possible to reduce models, multiplicity was taken into account by adjusting all pairwise 178 
comparisons using the Bonferroni method. Results were presented in terms of estimated 179 
means with 95% confidence intervals. Analyses were done based on two models: model 1 180 
was adjusted only for baseline measure of the outcome and site, and model 2 included 181 
adjustment for baseline measure of the outcome, age, sex, MUAC, WHZ and month of 182 
admission. Log transformations were applied to achieve normally distributed variables if 183 
needed and estimates were subsequently back-transformed (22). Effect modification was 184 
assessed for the factors and if present, investigated through sub-group analysis. Effect 185 
modification was assessed for the following variables: admission criteria (MUAC only, WHZ 186 
and MUAC, WHZ only), season, elevated CRP, elevated AGP, anemia, malaria and stunting 187 
at baseline. Model checking was based on residual and normal probability plots.  188 
 189 
Ethical considerations 190 
All children in need received treatment free of charge according to an adapted version of the 191 
Integrated Management of Childhood Illnesses guidelines (23,24) and the national protocol. 192 
Children who developed SAM during the intervention period were treated with ready-to-use 193 
therapeutic food (RUTF; Plumpy’Nut®, Nutriset, Malaunay, France). Children who did not 194 
recover from MAM during the trial subsequently received treatment with RUTF. If they did 195 
still not recover at the end of 4 weeks of supplementation with RUTF, they were referred to 196 
the hospital for medical investigation. Children who had an Hb <110 g/L at the end of the 197 
intervention period received iron and folic acid supplements; children who at any point had 198 
an Hb <50 g/L were referred to the hospital. The study was carried out in accordance with the 199 
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declaration of Helsinki. Consent was obtained from caregivers, prior to inclusion, verbally 200 
and in writing (signature or fingerprints). Data were kept confidential and in a locked facility. 201 
The study was approved by the Ethics Committee for Health Research of the government of 202 
Burkina Faso (2012-8-059) and consultative approval was obtained from the Danish National 203 
Committee on Biomedical Research Ethics (1208204). The trial was registered in the 204 
International Standard Randomized Controlled Trial Number registry under the number 205 
ISRCTN42569496.  206 
 207 
Results 208 
As previously described (16), of the 3398 children assessed, 1613 were randomized 209 
according to the 2x2x3 factorial design and four were later excluded as ineligible. A total of 210 
1609 children were enrolled in the study (Figure 1).  Baseline equivalence was achieved with 211 
regard to key potential confounders (Table 2).  Furthermore, there were no differences 212 
between treatment groups in proportion of children who consumed foods from any of 7 food 213 
groups, i.e. grains, legumes and nuts, dairy foods, eggs, flesh foods, vitamin A rich foods and 214 
other fruit and vegetables.  215 
 216 
Among the 1609 children who were randomized, 61 (3.8%) were lost to follow-up. Among 217 
the 1548 children who completed the intervention, 1546 (96.1%) children had baseline and 218 
end-line data for hemoglobin, 1523 (94.7%) for malaria and 1480 (92%) for iron status and 219 
inflammation biomarkers and were included in the ITT analysis. Children who developed 220 
SAM and were switched to RUTF (n=102), children who received ready-to-use 221 
supplementary foods (Plumpy’Sup®, Nutriset, Malaunay, France) because of an unconfirmed 222 
suspicion of Salmonella in one of the CSB products (n=17), and children who received iron 223 
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and folic acid supplements by error (n=69) or a combination were excluded from per protocol 224 
analysis (Figure 1). 225 
 226 
As previously described, mean baseline Hb was 100 ±16 g/L, median SFAI was 16 (8,30) 227 
µg/L and median sTFR was 12.6 (9.1,17.3) mg/L (15). Baseline Hb differed by admission  228 
criteria after adjusting for age and sex (p=0.001): it was 4 g/L (95% CI: 2, 7) higher in 229 
children admitted based on only low WHZ compared to those admitted based on low MUAC 230 
only and 3 g/L (95% CI: 1, 4) higher in children admitted based on low MUAC and WHZ 231 
compared to MUAC only. There were no differences in baseline SFAI and sTfR according to 232 
admission criteria. Hb increased by 7 g/L (95% CI: 6, 7) during the intervention (p<0.001), 233 
which corresponded to 16.9 percentage points drop in prevalence of anemia (Table 3). SFAI 234 
increased and sTfR, CRP and AGP decreased during the intervention period (p<0.001). 235 
Prevalence of low SFAI, elevated sTfR and IDA decreased 8.7, 12.6 and 10.5 percentage 236 
points, respectively. Prevalence of elevated CRP, elevated AGP and malaria decreased by 237 
5.9, 19.9 and 9.2 percentage points, respectively (Table 3).  238 
 239 
Impact of supplements on Hb and biomarkers of iron status 240 
Compared to CSB, LNS resulted in higher Hb (2 g/L, 1, 4), higher SFAI (4.2 µg/L, 2.9, 5.5) 241 
and lower sTfR (-0.9 mg/L, -1.3, -0.6) after adjustment for baseline measure, MUAC, WHZ, 242 
age, sex, month of admission and site (Table 4). Results were similar if adjusted only for 243 
baseline measure and site (Table 4) and in PP analysis (Supplemental Table 1). After the 244 
intervention, the prevalence of anemia was 8 percentage points lower (p=0.001), of low SFAI 245 
10 percentage points lower (P<0.001), and of elevated sTfR 5 percentage points lower 246 
(p=0.004) in children who had received LNS compared to children who received CSB 247 
supplements (Table 4). Similarly, the prevalence of IDA was 24.2% (n=183) in the CSB 248 
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group and 14.3% (n=110) in the LNS group after the intervention (p<0.001). There was no 249 
effect of soy quality and milk protein content in ITT (Supplemental Table 2 and 3) and PP 250 
analysis (Supplemental Table 1).  251 
 252 
Season modified the effect of LNS vs CSB on SFAI (interaction, p=0.02) and sTfR 253 
(interaction, p=0.007):  SFAI was 5.3 µg/L (95% CI: 3.7, 6.9) higher and sTfR 1.3 mg/L 254 
(95% CI: -1.7, -0.9) lower in children who had received LNS compared to CSB during the 255 
dry season but there was no difference during the rainy season. The effect of LNS vs CSB on 256 
Hb was modified by baseline AGP (interaction, p=0.03), whereby the effect of LNS was 257 
greater in children with elevated AGP at baseline (0.36 g/L, 95% CI: 0.2, 0.53) and was not 258 
significant if AGP was <1 g/L (0.04 g/L, 95% CI: -0.18, 0.27). The effect of LNS vs CSB on 259 
SFAI was modified by CRP (interaction, p=0.045) and malaria (interaction, p=0.02) at 260 
baseline, i.e. it was greater in children who had elevated CRP at baseline (6 µg/L, 95% CI: 261 
3.8, 8.2) than those who did not (3.2 µg/L, 95% CI: 1.5, 4.8) and in children with malaria 262 
(6.1, 95% CI: 4.1, 8.2) than those without (2.9 µg/L, 95%CI: 1.2, 4.6). We did not find any 263 
effect modification of admission criteria (MUAC only, WHZ and MUAC, WHZ only), 264 
anemia, low SFAI or elevated sTfR or stunting at baseline on Hb or biomarkers of iron status. 265 
 266 
Impact of supplements on acute phase proteins  267 
After the intervention, children who received LNS supplements had a 0.8 mg/L (95% CI: 0.4, 268 
1.2) higher mean CRP than those who received CSB (Table 4) after adjustment for baseline 269 
measure, MUAC, WHZ, age, sex, month of admission and site (Table 4). Results were 270 
similar if adjusted only for baseline measure and site (Table 4) and in PP analysis 271 
(Supplemental Table 1). The prevalence of elevated CRP was 4.5 percentage points higher 272 
among children who had received LNS compared to those who received CSB supplements 273 
16 
 
(Table 4). There was no effect of soy quality and milk protein content in ITT (Supplemental 274 
Table 2 and 3) and PP analysis (Supplemental table 1). We found an interaction between 275 
stunting and matrix, whereby the effect of LNS compared to CSB on CRP was greater in 276 
children who were stunted (1.2 mg/L, 95% CI: 0.7, 1.8 mg/L) than in those who were not (0.4 277 
mg/L, 95% CI: -0.12, 0.86). We did not find any effect modification between admission 278 
criteria, elevated acute phase proteins, anemia, low SFAI or elevated sTfR and malaria at 279 
baseline with any of the factors (interaction, p >0.05).  280 
 281 
Similarly to CRP, AGP was also higher in children who received LNS compared to those 282 
who received CSB. However, there was a significant 3-way interaction between the factors 283 
(p=0.03 in model 1, p=0.045 in model 2) whereby LNS-DS-50M led to higher AGP than 284 
LNS-SI-50M (0.2 g/L, 95% CI: 0.1, 0.4). Results were similar in PP analysis (Supplemental 285 
Table 1) but in the latter the interaction was not significant. There were no effects of soy 286 
quality or milk protein content in ITT analysis (Supplemental Table 2 and 3) or PP analysis 287 
(Supplemental Table 1). The effect of LNS vs CSB was modified by season (interaction, 288 
p=0.01), whereby AGP was higher in children who received LNS vs CSB if they were 289 
admitted during the rainy season (0.17g/L, 95% CI: 0.08, 0.26) compared to the dry season 290 
(0.03 g/L, 95%CI: -0.04, 0.09). 291 
 292 
Impact on malaria prevalence 293 
There was no effect of matrix (Table 4), quality of soy (Supplemental Table 2) and quantity 294 
of milk (Supplemental Table 3) on prevalence of malaria. Results were similar in the PP 295 
analysis. There were no interactions between any of the factors and season, admission 296 
criteria, anemia, low SFAI or elevated sTfR, CRP or AGP at baseline. 297 
 298 
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Discussion 299 
In this randomized trial we have shown that LNS was more effective in improving Hb and 300 
iron status than CSB but that concentrations of inflammatory markers were higher in children 301 
who received LNS. There was no impact of quality of soy and quantity of milk.  302 
Studies in children with MAM have previously reported better outcomes from LNS compared 303 
to CSB or CSB++ (also known as supercereal+) in terms of weight gain (6,9,25), MUAC 304 
gain and time to recovery (6). Better recovery rates have been found if LNS were compared 305 
to standard CSB (5,9,25) but not if compared to  CSB++ (6,26). Furthermore, based on data 306 
from the same trial, we have recently shown that gain of fat-free tissue and rates of 307 
anthropometric recovery were higher in children who received LNS compared to those who 308 
received CSBs (16). Data on the impact of supplements for treatment with MAM on Hb and 309 
iron status is, however, limited. One study carried out in Mali by Ackatia-Armah et al found 310 
lower concentrations of sTfR in children who received LNS compared to CSB++ or locally 311 
blended flours (26). In the same study, Ackatia-Armah et al also found higher Hb and SFAI 312 
in children who received LNS compared to a locally produced blended flour, but there was no 313 
difference between those who received LNS and CSB++ (26).  314 
 315 
Several possible mechanisms could explain the greater impact of LNS: better absorption of 316 
iron, better acceptability, or less sharing of the products. Absorption of iron from food 317 
depends on the type of iron, content of iron enhancers (e.g. vitamin C) or iron inhibitors (e.g. 318 
phytate), as well as iron stores of the individual and presence of infection (27). While 319 
products contained the same type of iron the amount of vitamin C or phytate may play a role.  320 
It has been estimated that 50% of vitamin C in CSB is lost during cooking (28). Double the 321 
amount of vitamin C was therefore added to CSB compared to LNS; while this should be 322 
sufficient, it is unclear how much vitamin C was present at the time of consumption since 323 
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losses depend on cooking time and temperature. Furthermore, the amount of soy products per 324 
daily serving of CSB, and thus phytate from soy, was on average double than that of the LNS. 325 
However, the total amount of phytate in the products is unknown since other ingredients, i.e. 326 
corn and peanuts, are also sources of phytate and no analysis of phytate content was carried 327 
out after production. We have previously shown that in this population, children and 328 
caregivers preferred LNS and that more leftovers were reported in CSB groups (17). The 329 
preference for LNS as well as the finding that appreciation of foods was greater and leftovers 330 
less during the rainy season when food availability is reduced (17) may also explain why the 331 
impact of LNS vs CSB on iron status was more pronounced during the dry season when a 332 
better availability of family foods may have led to more leftovers of the less preferred 333 
product. Furthermore, the effect of LNS vs CSB on Hb was greater in children who had 334 
elevated AGP. In line with this, the effect of LNS vs CSB on SFAI was greater in children 335 
with malaria or elevated CRP. While the latter could be an artefact since SFAI was adjusted 336 
for inflammation, the general trend of LNS having greater effect in children with infection or 337 
inflammation suggests that this may also have other reasons, such as the impact of infection 338 
on appetite. Lastly, while previous studies have shown that CSBs are more likely to be shared 339 
than LNS (29,30), this did not seem to be a problem in our study population (17).  340 
 341 
We did not find an effect of soy quality. However, while SI contains less phytate than DS, 342 
soy isolates do contain phytate, even small amounts of phytate have been shown to affect 343 
absorption, (31,32) and soy is not the only phytate-containing ingredient in the products. We 344 
did not find an effect of DSM quantity or an interaction between milk and soy. This means 345 
that reducing milk and replacing it with soy did not negatively impact iron status and this was 346 
not different if SI or DS was used. The lack of impact of milk may also be linked to the high 347 
breastfeeding rate, which was 95% at baseline. 348 
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While the prevalence of inflammation reduced throughout the intervention period, at the end 349 
of the intervention 20% of children had elevated CRP and 45% elevated AGP. This is not 350 
surprising considering the high burden of diseases in the study location (14). Higher 351 
concentrations of acute phase proteins in children who received LNS may be related to the 352 
higher linoleic acid content in LNS which can be converted to inflammatory metabolites via 353 
arachidonic acid (33) or the amount of absorbed iron. Iron status was better in children who 354 
received LNS at the end of the intervention indicating that more iron was absorbed. While 355 
iron is an essential nutrient, the safety of iron supplementation particularly in malaria-356 
endemic areas has been questioned (34,35). Even though a recent systematic review on this 357 
issue concluded that iron supplements can be given to children if services to treat and prevent 358 
malaria are provided (36), it is not clear whether iron supplementation would also be safe in 359 
malnourished children, where iron withholding mechanisms may be impaired.  In addition to 360 
iron supplementation, studies have also found higher morbidity among children who received 361 
micronutrient fortified complementary foods (37–39). We did not find an impact on malaria, 362 
which is not unexpected since participants received regular treatment for malaria and we only 363 
had data from rapid tests and not parasitemia. Nevertheless, the impact on inflammation 364 
reported here, which occurred despite regular medical follow-up and treatment for all 365 
identified infections, deserves further attention as both causes and implications are unclear. 366 
 455 
In this population of children with MAM, anemia was very common. The lower Hb in 456 
children admitted based on low MUAC only compared to those with low WHZ only at 457 
baseline may be linked to a higher prevalence of malaria in this group as previously reported 458 
(14). While the prevalence of anemia decreased during the intervention period, by 13% points 459 
in the CSB and 21% points in LNS group, the prevalence in both groups remained high after 460 
supplementation. Similar results have previously been reported (26). It is important to note 461 
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that, the iron content of the supplements was lower than therapeutic doses (40) and may have 462 
been insufficient particularly for children with a Hb <110 g/L. However, considering the 463 
large burden of infection and inflammation in this setting (14) it is unclear whether further 464 
supplementation would have been beneficial.  It is also worth mentioning that doubts about 465 
the validity of current cut-offs for definition of anemia have been raised (41–44) and the 466 
110g/L cut-off may be too high in young children living in Burkina Faso.   467 
 468 
This study had a number of strengths and limitations. First it is one of few studies 469 
investigating the effects of supplements on hemoglobin, iron status and inflammation in 470 
children with MAM. The use of a factorial design enabled us to assess the effect of three key 471 
factors in foods supplements and testing for interactions between the factors enabled us to 472 
investigate the potential impact of different combinations of these factors, e.g. whether 473 
removing DSM and adding more soy of different qualities and thus different amounts of anti-474 
nutrients affect iron status. However, a limitation of this design is that the ingredients differed 475 
somewhat between products, e.g. since SI contains more protein than DS, content of other 476 
ingredients had to be adapted to keep the overall energy and protein content constant. Other 477 
limitations include the lack of an unsupplemented control group, the lack of data on malaria 478 
parasitaemia and that we did not carry out a nutrient composition analysis to determine the 479 
total phytate content in the products and vitamin C content in CSB after cooking.  480 
 481 
In conclusion, we have shown that children supplemented with LNS had significantly better 482 
Hb and iron status at the end of the supplementation period than those who received CSB 483 
products but overall prevalence of anemia remained high. The higher concentrations of 484 
inflammation biomarkers reported in children who received LNS requires further 485 
investigation. 486 
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Matrix  Soy quality       Milk protein %       
    0 20 50 
 
Corn-soy blend  Dehulled  a b c 
 Isolate  d e f 
       
Lipid-based nutrient 
supplement 
 Dehulled  g h i 
 Isolate  j k l 
       
 
 
 
Table 1. The experimental food supplements based on corn-soy blend or lipid-based nutrient 
supplement, with either dehulled soy or soy isolate, and with 0, 20 or 50% of total protein from milk. 
Product "a" is similar to CSB+ (also known as Supercereal) and product "b" to CSB++ (also known as 
Supercereal+). Product “i” is similar to Plumpy´Sup®, (Nutriset, Malaunay, France), but 
Plumpy´Sup® contains whey instead of dry skimmed milk. 
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Table 2. Baseline characteristics of 1609 6-23 months old children enrolled in the study by factorial design1,2,3 
 
 Matrix Soy quality Milk protein % 
 CSB 
(n=800) 
LNS 
(n=809) 
Dehulled 
(n=800) 
Isolate 
(n=809) 
0% 
(n=541) 
20% 
(n=528) 
50% 
(n=540) 
Sociodemographic data      
Sex, male 356 (45) 374 (46) 373 (47) 357 (44) 246 (46) 241 (46) 243 (45) 
Age, months, median (IQR) 11 (8-16) 12 (8-16) 11 (8-16) 11 (8-16) 11 (8-16) 11 (8-16) 11 (8-16) 
Anthropometry 
       
MUAC, mm, mean (SD) 123 (4.0) 123 (4) 123 (4) 123 (4) 122 (4) 123 (4) 123 (4) 
WHZ, mean (SD) -2.2 (0.5) -2.2 (0.5) -2.2 (0.5) -2.2 (0.5) -2.2 (0.5) -2.2 (0.5) -2.2 (0.5) 
Admission by:        
  Low MUAC only 225 (28) 243 (30) 226 (28) 242 (29) 154 (29) 143 (27) 171 (32) 
  Low WHZ and low MUAC 404 (50) 400 (50) 406 (51) 398 (49) 276 (51) 275 (52) 253 (47) 
  Low WHZ only 171 (21) 166 (21) 168 (21) 169 (20) 111 (21) 110 (21) 116 (22) 
Morbidity 
       
Ill in the previous two weeks 303 (38) 305 (38) 318 (40) 290 (36) 207 (39) 206 (39) 195 (36) 
Positive malaria rapid test 324 (41) 320 (40) 322 (41) 322 (40) 216 (40) 207 (39) 221 (41) 
 
Breastfed 
 
755 (95) 
 
766 (95) 
 
755 (95) 
 
766 (95) 
 
515 (95) 
 
93 (93) 
 
513 (95) 
 
1Data are n (% of non-missing data) unless otherwise stated; 2 Data missing: ill in the previous two weeks (n=9), malaria rapid test (n=8), breastfeeding (n=2). 
3 Abbreviations: CSB= corn-soy blend, IQR=interquartile range; LNS=lipid nutrient supplements; MUAC=mid upper arm circumference; SD= standard deviation 
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Table 3. Changes in hemoglobin, biomarkers of iron status, inflammation and malaria prevalence in the full cohort during the 12-week supplementation period1,2 
 
 Baseline After supplementation Difference4  
 n  n  n  p 
Hemoglobin, g/L 1608 100 ± 16 1546 107 ± 14 1546 +7 (+6, +7) <0.001 
       % (n) < 110 g/L  1608 70.2 (1129) 1546 53.2  (821) 1546 -16.9 (-56.5, -12.6) <0.001 
SFAI, µg/L 1564 16 (8-30) 1511 18.1 (11.0-28.8) 1462 +2 (+1.2, +2.6) <0.001 
       % (n)  < 12 µg/L 1564 38.3 (595) 1511 29.3  (443) 1462 -8.7 (-14.5, -3.0) 0.004 
sTfR, mg/L 1564 12.6 (9.1-17.3) 1520 10.2 (8-13.5) 1480 -2.2 (-2.5, -2.0) <0.001 
       % (n) > 8.3 mg/L 1564 82.9  (1296) 1520 70.1  (1065) 1480 -12.6 (-16.0, -9.1) <0.001 
Iron deficiency anemia3, % (n) 1555 30.0 (469) 1511 19.4 (293) 1462 -10.5 (-16.8, -4.2) 0.001 
C-reactive protein,  mg/L 1564 2.3 (0.8-9.3) 1520 1.7 (0.6-6.2) 1480 -0.6 (-0.8, -0.4) <0.001 
       % (n) >10 mg/L 1564 25.4   (398) 1520 19.9   (302) 1480 -5.9 (-12.2, 0.2) 0.06 
α1-acid glycoprotein, g/L 1564 1.2 (0.9-1.6) 1520 1 (0.7-1.4) 1480 -0.21 (-0.24, -0.17) <0.001 
        % (n) >1 g/L 1564 66.4  (1039) 1520 45.7  (695) 1480 -19.9 (-24.6, -15.4) <0.001 
Rapid malaria test, % positive 1601 40.2 (644) 1531 31.3 (479) 1523 -9.2 (-14.8, -3.5) 
 
0.002 
1 Data are mean ± SD for hemoglobin, median (IQR) SFAI, sTfR, C-reactive protein, α1-acid glycoprotein or mean (95%CI) for the 
differences unless otherwise stated; 2 Abbreviations: SFAI, serum ferritin adjusted for inflammation; sTfR, serum soluble transferrin 
receptor; IQR, interquartile range; Iron deficiency anemia (IDA) was defined as hemoglobin < 110g/L and SFAI < 12 µg/L; 4Changes in 
concentrations before and after the intervention were assessed using t-tests. McNemar’s Chi2 was used to test for differences in proportions 
over time. 
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Table 4. Hemoglobin, markers of iron status and inflammation and malaria prevalence after 12 weeks of supplementation with CSB compared to LNS in the 
intention-to-treat population1,2 
       
  
CSB 
 
LNS 
Model 13 
Mean difference 
 
p 
Model 24 
Mean difference 
 
p 
Hemoglobin, g/L 105 ±14 108 ± 13 3 (1, 4)  <0.001 2 (1, 4) <0.001 
      % (n) < 110 g/L  57.4  (445) 49 (382)     
Serum ferritin, µg/L 23 [13-48.4] 30.6 [18-58.7] 9.5 (6.6, 12.3) <0.001 9.8 (7.02, 12.6) <0.001 
       % (n) < 12µg/L 22.1 (168) 11.3 (87)     
SFAI, µg/L 16.3 [9.5-25.5] 19.6 [12.2-30.9] 4.3 (2.9, 5.6) <0.001 4.2 (2.9, 5.5) <0.001 
       % (n) < 12µg/L 34.3 (257) 24.4 (186)     
sTfR, mg/L 10.6 [8.2-14.2] 9.8 [7.8-12.8] -1 (-1.4, -0.6) <0.001 -0.9 (-1.3, -0.6) <0.001 
       % (n) > 8.3mg/L 72.8 (549) 67.4 (516)     
C-reactive protein,  mg/L 1.4 (0.5-5.1) 2.2 [0.7-8.1] 0.7 (0.3, 1.1) <0.001 0.8 (0.4, 1.2) <0.001 
       % (n)>10 mg/L 17.6 (133) 22.1 (169)     
α1-acid glycoprotein, g/L 0.9 [0.7-1.4] 1 [0.7-1.5] 0.07 (0.02, 0.12)5 0.02 0.08 (0.02, 0.13)6 0.004 
        % (n)>1g/L 44.8 (344) 49.9 (389)     
Rapid malaria test, % (n) positive 29.7 (225) 32.9 (254) 3.1 (-1.6, 7.7) 0.19 2.7 (-1.0, 10.7) 0.16 
 
1 Data are mean ± SD for hemoglobin, median (IQR) for serum ferritin, SFAI, sTfR, C-reactive protein, α1-acid glycoprotein or mean difference (95% CI) unless 
otherwise stated. 
2 Abbreviations:  CSB, Corn-soy blend; DS, dehulled soy; IQR, interquartile range; LNS, lipid nutrient supplement; SFAI, serum ferritin adjusted for inflammation; 
SI, soy isolate; sTfR, serum soluble transferrin receptor. 
3 Results are based on linear mixed models for continuous outcomes and logistic mixed models for malaria adjusted only for baseline measure and site. 
4 Results are based on linear mixed models for continuous outcomes and logistic mixed models for malaria adjusted for baseline measure, mid-upper arm 
circumference, weight-for-height z-score, age, sex, month of admission and site. 
5 Interaction between matrix, soy quality and milk (p=0.03): LNS-DS-50% milk vs LNS-SI-50% milk= 0.22 (0.1; 0.44) 
6 Interaction between matrix, soy quality and milk (p=0.045): LNS-DS-50% milk vs LNS-SI-50% milk= 0.21(0.06; 0.42) 
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Figure 1. Trial Profile 
 
 
